Study of KSI-101 for swelling caused by eye inflammation
Part of Eyes & vision clinical trials.
This trial tests a new medicine called KSI-101 given as an injection into the eye to treat swelling in the center of the retina caused by inflammation. It may help people whose vision has gotten worse due to this type of swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have swelling in the center of the retina from inflammation, not from diabetes or other causes.
- The swelling in your study eye measures between 320 and 399 microns (thickness on a special scan).
- Your vision in the study eye is between 20/25 and 20/320 on an eye chart.
- You have fluid inside or under the retina in the study eye, seen on a special scan.
- You have been diagnosed with active or past non-infectious inflammation inside your study eye.
- You do not have an active eye infection or a history of blocked blood vessels causing swelling.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injected medicine (KSI-101) for people with swelling in the back of the eye caused by inflammation. The medicine is given directly into the eye to see if it can reduce the swelling and improve vision.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
This trial tests an eye injection called KIO-104 to treat macular edema (swelling in the center of the retina) caused by conditions like uveitis, diabetes, or vein blockage. The goal is to see if it is safe and improves vision.
Hear when a new Macular Edema Secondary to Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.